中国滤泡性淋巴瘤诊断与治疗指南(2020年版)

2020-07-30 中国抗癌协会淋巴瘤专业委员会 中华血液学杂志.2020,41(7):537-544.

滤泡性淋巴瘤(follicular lymphoma,FL)是B细胞淋巴瘤中的一种常见亚型,我们根据国际上相关指南及循证医学研究结果,结合目前我国淋巴瘤的诊治水平和现状制订中国FL 诊断与治疗指南(2

中文标题:

中国滤泡性淋巴瘤诊断与治疗指南(2020年版)

发布日期:

2020-07-30

简要介绍:

滤泡性淋巴瘤(follicular lymphoma,FL)是B细胞淋巴瘤中的一种常见亚型,我们根据国际上相关指南及循证医学研究结果,结合目前我国淋巴瘤的诊治水平和现状制订中国FL 诊断与治疗指南(2020年版)。

相关资料下载:
[AttachmentFileName(sort=1, fileName=中国滤泡性淋巴瘤诊断与治疗指南(2020年版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=d49761c00196e636, title=中国滤泡性淋巴瘤诊断与治疗指南(2020年版), enTitle=, guiderFrom=中华血液学杂志.2020,41(7):537-544., authorId=0, author=, summary=滤泡性淋巴瘤(follicular lymphoma,FL)是B细胞淋巴瘤中的一种常见亚型,我们根据国际上相关指南及循证医学研究结果,结合目前我国淋巴瘤的诊治水平和现状制订中国FL 诊断与治疗指南(2, cover=https://img.medsci.cn/2020910/1599670728604_2020535.jpg, journalId=0, articlesId=null, associationId=1417, associationName=中国抗癌协会淋巴瘤专业委员会, associationIntro=, copyright=0, guiderPublishedTime=Thu Jul 30 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>滤泡性淋巴瘤(follicular lymphoma,FL)是B细胞淋巴瘤中的一种常见亚型,我们根据国际上相关指南及循证医学研究结果,结合目前我国淋巴瘤的诊治水平和现状制订中国FL 诊断与治疗指南(2020年版)。</p> </div> </div> </div>, tagList=[TagDto(tagId=10568, tagName=滤泡性淋巴瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=10568, guiderKeyword=滤泡性淋巴瘤, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7584, appHits=653, showAppHits=0, pcHits=2211, showPcHits=6930, likes=3, shares=48, comments=21, approvalStatus=1, publishedTime=Thu Sep 10 01:37:10 CST 2020, publishedTimeString=2020-07-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Thu Sep 10 00:58:59 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 14:02:47 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=中国滤泡性淋巴瘤诊断与治疗指南(2020年版).pdf)])
中国滤泡性淋巴瘤诊断与治疗指南(2020年版).pdf
下载请点击:
评论区 (16)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1199926, encodeId=b05f119992685, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec22608622, createdName=gujie_happy, createdTime=Sun Mar 06 16:22:19 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179362, encodeId=852e11e936256, content=r怎么样弄积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffdc6420949, createdName=ms3000000645034296, createdTime=Fri Dec 31 16:41:54 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005529, encodeId=9df010055295f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/07/3a24b0a671b46b7af59cc79b24620382.jpg, createdBy=ca7f5316479, createdName=1489b925m48暂无昵称, createdTime=Fri Aug 06 07:47:44 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999765, encodeId=8cbd999e65d4, content=学习了,谢谢。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=938a5549722, createdName=ms8000002017564698, createdTime=Thu Jul 15 15:27:08 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998457, encodeId=e6a299845e12, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fec2067476, createdName=特立独行的红猪, createdTime=Sun Jul 11 12:01:54 CST 2021, time=2021-07-11, status=1, ipAttribution=)]
    2022-03-06 gujie_happy

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1199926, encodeId=b05f119992685, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec22608622, createdName=gujie_happy, createdTime=Sun Mar 06 16:22:19 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179362, encodeId=852e11e936256, content=r怎么样弄积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffdc6420949, createdName=ms3000000645034296, createdTime=Fri Dec 31 16:41:54 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005529, encodeId=9df010055295f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/07/3a24b0a671b46b7af59cc79b24620382.jpg, createdBy=ca7f5316479, createdName=1489b925m48暂无昵称, createdTime=Fri Aug 06 07:47:44 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999765, encodeId=8cbd999e65d4, content=学习了,谢谢。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=938a5549722, createdName=ms8000002017564698, createdTime=Thu Jul 15 15:27:08 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998457, encodeId=e6a299845e12, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fec2067476, createdName=特立独行的红猪, createdTime=Sun Jul 11 12:01:54 CST 2021, time=2021-07-11, status=1, ipAttribution=)]
    2021-12-31 ms3000000645034296

    r怎么样弄积分

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1199926, encodeId=b05f119992685, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec22608622, createdName=gujie_happy, createdTime=Sun Mar 06 16:22:19 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179362, encodeId=852e11e936256, content=r怎么样弄积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffdc6420949, createdName=ms3000000645034296, createdTime=Fri Dec 31 16:41:54 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005529, encodeId=9df010055295f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/07/3a24b0a671b46b7af59cc79b24620382.jpg, createdBy=ca7f5316479, createdName=1489b925m48暂无昵称, createdTime=Fri Aug 06 07:47:44 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999765, encodeId=8cbd999e65d4, content=学习了,谢谢。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=938a5549722, createdName=ms8000002017564698, createdTime=Thu Jul 15 15:27:08 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998457, encodeId=e6a299845e12, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fec2067476, createdName=特立独行的红猪, createdTime=Sun Jul 11 12:01:54 CST 2021, time=2021-07-11, status=1, ipAttribution=)]
    2021-08-06 1489b925m48暂无昵称

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1199926, encodeId=b05f119992685, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec22608622, createdName=gujie_happy, createdTime=Sun Mar 06 16:22:19 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179362, encodeId=852e11e936256, content=r怎么样弄积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffdc6420949, createdName=ms3000000645034296, createdTime=Fri Dec 31 16:41:54 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005529, encodeId=9df010055295f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/07/3a24b0a671b46b7af59cc79b24620382.jpg, createdBy=ca7f5316479, createdName=1489b925m48暂无昵称, createdTime=Fri Aug 06 07:47:44 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999765, encodeId=8cbd999e65d4, content=学习了,谢谢。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=938a5549722, createdName=ms8000002017564698, createdTime=Thu Jul 15 15:27:08 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998457, encodeId=e6a299845e12, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fec2067476, createdName=特立独行的红猪, createdTime=Sun Jul 11 12:01:54 CST 2021, time=2021-07-11, status=1, ipAttribution=)]
    2021-07-15 ms8000002017564698

    学习了,谢谢。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1199926, encodeId=b05f119992685, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec22608622, createdName=gujie_happy, createdTime=Sun Mar 06 16:22:19 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179362, encodeId=852e11e936256, content=r怎么样弄积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ffdc6420949, createdName=ms3000000645034296, createdTime=Fri Dec 31 16:41:54 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005529, encodeId=9df010055295f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/04/07/3a24b0a671b46b7af59cc79b24620382.jpg, createdBy=ca7f5316479, createdName=1489b925m48暂无昵称, createdTime=Fri Aug 06 07:47:44 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999765, encodeId=8cbd999e65d4, content=学习了,谢谢。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=938a5549722, createdName=ms8000002017564698, createdTime=Thu Jul 15 15:27:08 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998457, encodeId=e6a299845e12, content=学习了,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5fec2067476, createdName=特立独行的红猪, createdTime=Sun Jul 11 12:01:54 CST 2021, time=2021-07-11, status=1, ipAttribution=)]
    2021-07-11 特立独行的红猪

    学习了,谢谢

    0

拓展阅读

2016 ESMO临床诊疗指南:新诊断和复发性滤泡性淋巴瘤的诊断、治疗与随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2016-09-20

2018 JSH实践指南:血液恶性肿瘤—淋巴瘤:滤泡性淋巴瘤

日本血液学会(JSH,Japanese Society of Hematology) · 2019-06-06

2020 BSH指南:滤泡性淋巴瘤的调查和管理

英国血液病学学会(BSH,British Society for Haematology) · 2020-06-24

2023 NICE 技术鉴定指导意见:莫妥珠单抗用于治疗复发或难治性滤泡性淋巴瘤[TA892]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2023-05-31

2023 NICE 技术鉴定指导意见:阿基仑赛用于治疗复发或难治性滤泡性淋巴瘤[TA894]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2023-06-07